The original. Exenatide is a synthetic version of exendin-4, a peptide isolated from the venom of the Gila monster, which shares roughly 53% sequence identity with human GLP-1 and — crucially — resists DPP-4 cleavage naturally. Its discovery is the reason this entire drug class exists: it demonstrated that a degradation-resistant GLP-1 receptor agonist was pharmacologically viable.
First-in-class, approved in 2005. Superseded in potency and convenience by later agents, and now of more historical than clinical interest, but the trial base is long-established.
FDA-approved for type 2 diabetes. Prescription-only. Some formulations have been discontinued commercially.
Boxed warning on the extended-release formulation for rodent thyroid C-cell tumours. Pancreatitis signal. Renal impairment cautions. Physician supervision required.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.